Spoken Alpha
EW
Edwards Lifesciences Corp
Overview
Edwards Lifesciences manufactures and sells transcatheter and surgical heart valve replacement and repair systems for patients with structural heart disease.
Edwards Lifesciences Corp is a Healthcare company operating in Medical Devices with a $49.84B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 22, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-02-1014 Q&A exchanges
- Q3 FY2025Earnings2025-10-3012 Q&A exchanges
- Q2 FY2025Earnings2025-07-2418 Q&A exchanges
- Q1 FY2025Earnings2025-04-2328 Q&A exchanges
- Q4 FY2024Earnings2025-02-1127 Q&A exchanges
- Q3 FY2024Earnings2024-10-2419 Q&A exchanges
- Q2 FY2024Earnings2024-07-2422 Q&A exchanges
- Q1 FY2024Earnings2024-04-2526 Q&A exchanges
- Q4 FY2023Earnings2024-02-0628 Q&A exchanges
- Q3 FY2023Earnings2023-10-2626 Q&A exchanges
- Q2 FY2023Earnings2023-07-2617 Q&A exchanges
- Q1 FY2023Earnings2023-04-2630 Q&A exchanges
- Q4 FY2022Earnings2023-01-3126 Q&A exchanges
- Q3 FY2022Earnings2022-10-2722 Q&A exchanges
- Q2 FY2022Earnings2022-07-2821 Q&A exchanges
- Q1 FY2022Earnings2022-04-2622 Q&A exchanges
- Q4 FY2021Earnings2022-01-2641 Q&A exchanges
- Q3 FY2021Earnings2021-10-2735 Q&A exchanges
- Q2 FY2021Earnings2021-07-3040 Q&A exchanges
- Q1 FY2021Earnings2021-04-2026 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-22EPS— vs $0.74—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-22 | — | $0.74 | — | — | — | — | EODHD |
Source: EODHD. EW reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks EW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $2.81 | $3.27 | -14.0% | -6.1% | -5.1% |
| Q4 FY2025 | $2.88 | $3.07 | -6.3% | +1.3% | -0.7% |
| Q3 FY2025 | $2.41 | $3.09 | -22.0% | -0.9% | -2.2% |
| Q2 FY2025 | $3.03 | $3.37 | -10.0% | -3.6% | -2.2% |
| Q1 FY2024 | $2.76 | $3.14 | -12.1% | -6.6% | -5.9% |
| Q4 FY2024 | $3.06 | $3.30 | -7.2% | +1.8% | +3.0% |
| Q3 FY2024 | $3.08 | $3.33 | -7.5% | +1.7% | +2.6% |
| Q2 FY2024 | $2.84 | $3.30 | -13.9% | -2.9% | -5.2% |
| Q1 FY2023 | $3.04 | $3.24 | -6.1% | -4.0% | -5.0% |
| Q4 FY2023 | $2.89 | $3.43 | -15.6% | -1.6% | -1.1% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
- Q1 FY2024Lowered2024-04-15
- Q4 FY2024Lowered2024-13-15
- Q3 FY2024Lowered2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Bernard J ZovighianCEO1 yr 1 mo15 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2025
- Scott B UllemCFO7 mo20 callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2025
- Larry L WoodPresident1 yr12 callsCurrentSample
PRESIDENT since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2025
- Andrew M DahlSVP, Corporate Controller9 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/2 beats (100%) • last guidance raise Q3 FY2025
- Daniel J LippisCVP, TAVR5 mo2 callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2025
- Donald E Bobo JrCVP,Strategy/Corp Development6 mono recorded callsCurrentSample
OTHER since 2025 • 1/2 beats (50%) • guidance suspended Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for EW.
$ curl https://api.spokenalpha.com/v1/companies/EWFAQ
Frequently asked about EW
Where can I find Edwards Lifesciences Corp's (EW) earnings call transcripts?
Spoken Alpha indexes EW's earnings call transcripts at https://spokenalpha.com/companies/EW. Each call links to attributed speakers and parsed analyst Q&A. Edwards Lifesciences Corp's own investor relations page is at https://ir.edwards.com/overview/default.aspx.
When was Edwards Lifesciences Corp's most recent earnings call?
Edwards Lifesciences Corp (EW) held its most recent earnings call on 2026-02-10, covering fiscal Q4 2025.
What sector is EW in?
Edwards Lifesciences Corp (EW) operates in the Healthcare sector (Medical Devices industry).